iCAD jumps on 3-year Xoft data

iCAD (ICAD +2.3%) shares jump after the company presents positive 3-year data for non-melanoma skin cancer treatment efficacy of its Xoft System at the American Society of Radiation Oncology's annual meeting.

The study showed "good cosmesis, low toxicity levels and no recurrences" across a 187 patient cohort.

Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs